HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dermatology Among Emerging Rx-To-OTC Switch Categories

This article was originally published in The Rose Sheet

Executive Summary

FDA threw the switch floodgates open with the Nonprescription Safe Use Regulatory Expansion (NSURE) initiative and has fueled interest with recent first-in-class switches of Nasacort and Oxytrol for Women. Experts say likely categories for successful switches include dermatology, as drugs for treating eczema, acne and other skin conditions typically do not have systemic effects and address ailments that are readily recognized and understood by consumers.

You may also be interested in...

Galderma Acne Ingredient Rx-to-OTC Switch Headed For NDAC In April

FDA schedules an April 15 NDAC meeting to consider whether data in Galderma's supplemental NDA support an acceptable risk/benefit profile for nonprescription use of adapalene gel 0.1.

Dermocosmetic Market Ripens With Uptake Of FDA-Approved Drug Ingredients

The market for specialized dermocosmetics is expanding rapidly as big beauty marketers join the fray with products containing OTC-approved drug ingredients for hair and skin care, says Euromonitor Beauty & Personal Care analyst Nicholas Micallef. Coal tar, ketoconazole and salicylic acid are among approved drug ingredients increasingly making their way into beauty.

Oxytrol For Women Gets OTC Green Light As Rare First-In-Class Switch

FDA approved Merck’s overactive bladder drug Oxytrol for Women for OTC use, despite concerns raised by the Nonprescription Drug Advisory Committee in November. The company plans a launch in the fall.

Related Content

Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts